- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000936
A Study To Test An Anti-Rejection Therapy After Kidney Transplantation
Controlled Trial of Induction Therapy in Renal Transplantation
Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective.
Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Renal transplantation is recognized as the treatment of choice for children with chronic renal failure. However, patient and graft survival rates in young children are unacceptably low. In preliminary studies, OKT3 (a monoclonal antibody) induction therapy received post transplant has been more successful than standard immunosuppression alone in improving graft survival. This study is designed to assess the impact of induction therapy on graft survival in pediatric kidney transplant patients.
Patients are assigned to OKT3 induction or no induction in a 1:1 ratio. Randomization to oral cyclosporine of either Sandimmune or Neoral is also done in a 1:1 ratio. Group 1 receives OKT3 intraoperatively followed by Neoral. Group 2 receives OKT3 intraoperatively followed by Sandimmune. OKT3 is administered at 2.5 mg (if weight less than 30 kg) or 5 mg (if weight above 30 kg) per day for a maximum of 14 days. Group 3 receives IV cyclosporine followed by Neoral. Group 4 receives IV cyclosporine followed by Sandimmune. Oral cyclosporine is administered in a masked preparation. The dose for Sandimmune and Neoral is the same; patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day. Patients will receive concomitant medications including steroids (IV and po), Nifedipine, anti-CMV therapy, Bactrim, Azathioprine or Mycophenolate Mofetil. Kidney function, incidence of viral infection, graft survival, and incidence of malignancy will be measured to assess the role of OKT3 induction and the role of rejection in graft failure. Graft function will be evaluated at 1-, 2-, and 4-year intervals.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Ilene Blechman-Krom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Children and young adults may be eligible for this study if they:
- Are not yet 21 years of age.
- Are receiving their first or second transplant.
- Are not pregnant.
- Agree to practice sexual abstinence or agree to use an effective
- method of birth control/contraception during the study and
- for 1 year after.
Exclusion Criteria
Children and young adults will not be eligible for this study if they:
- Are recipients of multiple organs other than kidneys.
- Are recipients of three or more transplants.
- Are HIV positive.
- Are Hepatitis B surface antigen positive.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Induction
subjects receiving hOKT3 induction therapy
|
Administered both during and after transplantation in IV form.
Dosage determined by individual weight and given for a maximum of 14 days.
Administered orally as either sandimmune or neoral at a dose determined by weight.
Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
|
ACTIVE_COMPARATOR: Induction Free Therapy
Patients not receiving induction therapy
|
Administered orally as either sandimmune or neoral at a dose determined by weight.
Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine one-year graft function, as measured by graft survival and serum creatinine of children undergoing OKT3 induction versus no induction
Time Frame: At 1 year
|
At 1 year
|
To compare the efficacy of Sandimmune and Neoral with respect to graft function
Time Frame: Throughout study
|
Throughout study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Two and four-year graft functions
Time Frame: At 2 and 4 years
|
At 2 and 4 years
|
Safety with respect to viral infections and malignancies in children undergoing a renal transplant
Time Frame: Throughout study
|
Throughout study
|
Frequency and severity of rejection episodes
Time Frame: Throughout study
|
Throughout study
|
Time to first rejection
Time Frame: Throughout study
|
Throughout study
|
Length and frequency of hospitalization
Time Frame: Throughout study
|
Throughout study
|
Nature of acute cellular rejection at a molecular level
Time Frame: Throughout study
|
Throughout study
|
Nature of "heightened immune response" of younger children by studying gene expression in surveillance biopsies
Time Frame: Throughout study
|
Throughout study
|
Correlate intragraft events during rejection with cytokine profile in the peripheral blood
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAIT IN01/OLN-359
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Individual Participant Data Set
Information identifier: SDY354Information comments: ImmPort study identifier is SDY354.
-
Study Protocol
Information identifier: SDY354Information comments: ImmPort study identifier is SDY354.
-
Study summary, -design, -demographics, -lab tests, -study files
Information identifier: SDY354Information comments: ImmPort study identifier is SDY354.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation